Original Article

In Vitro Study of Leishmanicidal Activity of Biogenic Selenium Nanoparticles against Iranian Isolate of Sensitive and Glucantime-Resistant Leishmania tropica

Hossein MAHMOUDVAND 1,2, Mojtaba SHAKIBAIE 3, Razieh TAVAKOLI 1, Sareh JAHANBAKHSH 1, *Iraj SHARIFI 2

1. Research Center for Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
2. Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran
3. Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

Received 19 Apr 2014
Accepted 11 Sep 2014

Abstract

Background: Sensitive and glucantime (MA) resistance Leishmania tropica are referred to those isolates, which are responsive, or non-responsive to one or two full courses of treatment by MA systematically and/or intra-lesionally, respectively. In this study, we evaluated the antileishmanial activity of biogenic selenium nanoparticles (Se NPs) alone and in combination with MA against sensitive and glucantime-resistant L. tropica on in vitro model.

Methods: The Se NPs were synthesized by employing the Bacillus sp. MSh-1. The antileishmanial effects of Se NPs alone and in combination with MA on promastigote and amastigote stages of sensitive and glucantime-resistant L. tropica strains have been investigated using a colorimetric MTT assay and in a macrophage model. In addition hemolytic activity in type O+ human red blood cells and infectivity rate of the promastigotes before and after treatment with the Se NPs was evaluated.

Results: In the promastigote stage, various concentrations of Se NPs significantly inhibited (P<0.05) the growth of promastigotes of both strains in a dose-dependent manner. Similarly, Se NPs especially in combination with MA significantly reduced the mean number of amastigotes of both strains in each macrophage. Se NPs showed no hemolytic effect on human RBCs at low concentrations. Moreover, infection rate of macrophages by promastigotes significantly (P<0.05) was reduced when promastigotes pre-treated with Se NPs.

Conclusion: The findings of this study suggest a first step in the search of Se NPs as a new antileishmanial agent. Further experiments are needed to investigate antileishmanial effects of biogenic Se NPs on L. tropica using a clinical setting.

Keywords: Cutaneous leishmaniasis, Selenium nanoparticles, Promastigote, Amastigote, Glucantime resistant

*Correspondence Email: iraj.sharifi@yahoo.com

Available at: http://ijpa.tums.ac.ir
Introduction

Leishmaniasis is one of the most important public health problems in tropical and sub-tropical countries. It is endemic in 98 countries and territories, affecting 12 million people and approximately threatens 350 million, worldwide (1). It consists several different presentations including cutaneous, mucocutaneous and visceral forms. In Iran, there are two epidemiological forms of cutaneous leishmaniasis (CL); Anthropo- notic CL (ACL) and zoonotic CL (ZCL) caused by Leish mania tropica and L. major, respectively (2, 3).

At present, because there is not any effective vaccine; the effective control approach is prompt detection of the cases and early treatment against leishmaniasis (4, 5). Although, antimonial compounds such as meglumine antimoniate have been used as the treatment of choice, resistance has frequently been reported for L. tropica and L. donovani, the two Old World anthropo- notic leishmaniasis for many years (6-8). These species have developed resistance as reported from Africa, Indian sub-continent, South-east Asia particularly Iran (1). This problem indicates the urgent needs for development of new drugs or combination therapy for treatment of CL. However, extensive efforts have also been made to promote combination therapy of available drugs including verapamil, imiquimod and allopurinol that revealed synergistic effects with MA in the treatment of CL (9-11).

Selenium (Se) is a trace element of fundamental importance to human health. It is a component of selenoproteins, some of which have important enzymatic functions (12). Selenium has been used in various medical therapies such as cancer prevention including lung, esophagus, prostate and gastric-cardiac cancers, antiviral activities and antioxidant effects (13-15). Moreover, Se has additional important health activities relevant to the immune response and successful reproduction (15). It has currently been demonstrated that nanoparticles (NPs) due to their large surface-volume ratio show various unique properties such as enhancing interactions with biological molecules and microorganisms. NPs are also able to enter cells more frequently than other particles (16). NPs particularly Se NPs can effectively inhibit the growth of some bacteria such as Staphylococcus aureus and pathogenic Escherichia coli (16, 17). In addition, Se NPs significantly inhibited the growth of Echinococcus granulosus protoscoleces and L. major on in vitro and in vivo model (18, 19).

In this study, we synthesized the biogenic Se NPs by employing the Bacillus sp. MSh-1 as a potent bacterium in selenium reduction. In the next step, to separate and purify Se NPs from the whole-cell lysate, we used a liquid-liquid two-phase partitioning method. After characterisation of the purified Se NPs, the effect of Se NPs on L. tropica promastigotes was studied by MTT assay. Finally, the antileishmanial activity of NPs on clinical stage was evaluated in an amastigote-macrophage model.

Materials and Methods

Chemicals

Meglumine antimoniate (MA, Glucantime) as control drug was prepared from Rhone, Poulenc, France. Penicillin and streptomycin were obtained from Alborz Pharmacy, Karaj, Iran and were stored at room temperature (25°C) until testing. MTT powder [3-(4,5- dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide], fetal calf serum (FCS) and RPMI-1640 medium with L-glutamine were purchased from Sigma-Aldrich, St Louis, MO. Selenium dioxide (SeO₂), nutrient broth, nutrient agar, n-octyl alcohol, sodium dodecyl sulfate (SDS) and Tris base were purchased from Merck Chemicals (Germany). All other chemicals and solvents were of analytical grade. The microorganism used in this study was identified as Bacillus sp. MSh-1 by the methods described earlier (12). The organism was continuously maintained on nutrient agar plates.
complemented with 1.26 mM SeO$_3$ using continuous sub-culturing every 14 days.

**Biosynthesis and characterization of the Se NPs**

Se NPs were prepared according to the method described elsewhere (12). Briefly, a sterile nutrient broth (NB) medium was supplemented with the Se$^{4+}$ ions (100 mg/L; equal to 1.26 mM SeO$_2$ solution) and 100 mL of this medium was transferred to a 500-mL Erlenmeyer flask. The medium was inoculated with 1 mL of the fresh inoculums (OD$_{600}$ 0.1) of *Bacillus* species MSh-1 and was incubated aerobically at 30°C in a shaker incubator (150 rpm). After 14 h, the bacterial cells and Se NPs were removed from the culture medium by using centrifugation at 4000 g for 10 min. The pellets were washed with 0.9% NaCl solution using centrifugation, transferred to a mortar and then it was frozen by adding liquid nitrogen and was then disrupted by a pestle. The resulting slurry was ultrasonicated at 100 W for 5 min and washed three times by sequential centrifugation (10000 g for 5 min), with a 1.5 M Tris-HCl buffer (pH 8.3) containing 1% SDS and deionized water. The next step involved extracting and purifying the Se NPs through an organic-aqueous partitioning system (n-octyl alcohol-water). For transmission electron microscopy, an aqueous suspension containing the Se NPs was dispersed ultrasonically, and a drop of the suspension was placed on carbon-coated copper TEM (transmission electron microscope) grids and dried under an IR lamp. The crystalline structure of the Se NPs was evaluated by the X-ray diffraction (XRD) technique using an X-ray diffractometer (Philips PW1710) with CuK$_{a}$ radiation (λ = 1.5405 Å) over a scanning range of Bragg angles from 20 to 80°C.

**Parasite strains and culture**

Glucantime-resistant strain of *L. tropica* was prepared from a CL patient in Bam, southeastern Kerman province of Iran. This isolate was identified by nested-PCR as *L. tropica* and further determined by conventional PCR for *MDR1* gene (8). Subsequently the DNA extract was sequenced and recorded in Gen Bank under HM854717 Accession Number. Sensitive (MHOM/IR/2002/Mash2) strain of *L. tropica* was kindly provided by the Center for Research and Training in Skin Diseases and Leprosy (Tehran, Iran). The parasite was cultured in RPMI-1640, supplemented with penicillin (100 IU/mL), streptomycin (100 μg/mL), and 15% heat-inactivated fetal calf serum (FCS).

**Preparation of murine macrophages**

In this study, murine macrophage cells were collected from male BALB/c mice (5-8 weeks old) by injecting 3.5 mL of cold RPMI-1640 medium into mouse peritoneal cavity and aspirated macrophages were washed twice and resuspended in RPMI-1640 medium. The experimental procedures carried out in this study complied with the guidelines of the Kerman University of Medical Science (Kerman, Iran) for the care and use of laboratory animals.

**Leishmanicidal activity against promastigotes**

Leishmanicidal activity of Se NPs on promastigote forms of sensitive and glucantime-resistant strains of *L. tropica* was evaluated by colorimetric cell viability MTT assay using the method described by Mahmoudvand et al. (20). Initially, 100 μL of the promastigotes (10$^5$cells/mL) harvested from logarithmic growth phase was added into a 96-well microtiter plate. Then 100 μL of different concentrations of Se NPs alone (0-25 μg/mL) or MA alone (0-25 μg/mL) and along with Se NPs (2 μg/mL) was added to each well and incubated at 25°C ± 1°C for 72 h. After incubation 10 μL of MTT solution (5 mg/mL) was added into each wells and were incubated at 25°C for 4 h. Promastigotes cultured in complete medium with no drug used as positive control, and complete medium with no promastigotes and drugs as blank. All experiments were repeated in triplicate. Finally, absorbance was measured available at: [http://ijpa.tums.ac.ir](http://ijpa.tums.ac.ir)
by an ELISA reader (BioTek-ELX800) at 490 nm. We also calculated the 50% inhibitory concentrations (IC_{50} values) by Probit test in SPSS software.

**Effects on intramacrophage amastigotes**

For evaluation of antileishmanial activity of Se NPs on *L. tropica* intracellular amastigotes, murine macrophages collected from male BALB/c mice were used according to the method described elsewhere (21). Briefly, 1cm² cover slips were placed in the wells of 4-chamber slides (Lab-Tek, Nalg Nunc International NY, USA) and then 200 μL of the murine macrophages (10^5 cells/mL) was placed in each well. After 2 h, promastigotes of each strain were added to each well and were incubated at 37°C in a CO₂ incubator (5% CO₂ and 95% relative humidity). After 24 h free parasites were removed by washing with RPMI-1640 medium and infected macrophages were treated with different concentrations of Se NPs alone (0-50 μg/mL) or MA alone (0-50 μg/mL) and along with Se NPs (5 μg/mL) for 72 h. Finally, dried slides were fixed with methanol, stained by Giemsa and studied under a light microscope. In this step, macrophages containing amastigotes without treatment and macrophages with no parasite and treatment were considered as positive and negative controls, respectively. Antileishmanial activity of treatments and the mean number of amastigotes were evaluated by counting the number of amastigotes in 100 macrophages (9). All experiments were carried out in triplicate. In addition, the IC_{50} values were calculated by Probit analysis.

**Inhibition of infection in macrophage cells**

The inhibitory effect of the Se NPs on the *Leishmania* invasion of macrophages was investigated in promastigote forms of sensitive and Glucantime-resistant strains of *L. tropica*. Firstly, promastigotes in the stationary phase were pre-incubated with Se NPs (1 μg/mL) for 1 h at 37°C. In the next step, promastigotes were washed with RPMI-1640 medium and further incubated for 4 h with murine macrophages at a ratio of 10 *Leishmania* per 1 macrophage. After washing, the macrophages were fixed with methanol, stained by Giemsa and studied by a light microscope and frequency of infected macrophages was measured by counting 100 macrophages (22).

**Hemolytic activity of Se NPs**

The hemolytic activity was evaluated by incubating the various concentrations of Se NPs (0-200 μg/mL) with a 5% O+ human red blood cells (RBC) suspension for 1 h at 37°C. The erythrocyte suspension was centrifuged (1000 g for 10 min), and cell lysis was determined spectrophotometrically (540 nm), as described (23). The absence (blank) or 100% presence of hemolysis (positive control) was determined by replacing the Se NPs for an equal volume of PBS 1x or distilled water, respectively. The results were calculated by the percentage of hemolysis compared to the negative and positive controls.

**Statistical analysis**

SPSS Software ver. 17 (SPSS Inc., Chicago) was used for data entry and statistical analysis and the differences between groups were determined by using one way analysis of variance (ANOVA) test. Moreover, to compare the IC_{50} values of Se NPs and control drug t-test performed. P-value of less than 0.05 was considered statistically significant.

**Results**

**Characterization of Se NPs**

Figure 1 shows the TEM image of Se NPs. The TEM micrograph clearly illustrates individual Se NPs with a small amount of aggregation and the NPs have a spherical shape. Size distribution measured from manual counting of 400 individual particles from different TEM images showed that the size of nanoparticles was 80-220 nm and NPs with the size of 105 to 130 nm had the most frequency. The XRD pattern of Se NPs showed

Available at: http://ijpa.tums.ac.ir
the presence of broad peaks without any clear lattice parameters (results not shown). Thus the obtained Se NPs are amorphous.

**Fig. 1:** Transmission electron micrograph of the purified selenium nanoparticles (Se NPs) synthesized by *Bacillus* sp. MSh-1

**Leishmanicidal activity against promastigotes**

In contrast to controls, various concentrations of Se NPs alone or combined with MA significantly inhibited (*P*<0.05) the growth rate of promastigotes of both strains in a dose-dependent manner. The measured IC$_{50}$ values of Se NPs for sensitive and glucantime-resistant strains were 2.7 and 3.6 μg/mL, respectively. Similarly, the IC$_{50}$ values of MA plus Se NPs for sensitive and glucantime-resistant strains were 1.5 and 2.8 μg/mL, respectively. In contrast, the IC$_{50}$ values of MA for sensitive and glucantime-resistant strains were 11.6 and 43.6 μg/mL, respectively, which are significantly (*P*<0.05) higher than the measured IC$_{50}$ values for Se NPs alone and along with MA against both strains of *L. tropica*, reflecting more effective leishmanicidal effects of Se NPs alone and along with MA as compared with MA alone upon promastigotes of both strains of *L. tropica* (Table 1).

**Table 1:** Comparison of the mean IC$_{50}$ values of meglumine antimoniate (MA), biogenic selenium nanoparticles (Se NPs) alone and combined with MA upon the growth rate of promastigote and amastigote forms of sensitive and glucantime-resistant strains of *L. tropica*. Data are expressed as the mean ± SD (*n* = 3)

| Chemicals       | IC$_{50}$ (μg/mL) | Promastigotes | Amastigotes |
|-----------------|-------------------|---------------|-------------|
|                 |                   | SS$^a$        | RS$^b$      | SS          | RS          |
| MA              | 11.6 ± 1.55       | 43.6 ± 3.05   | 39.2 ± 2.52 | 151 ± 4.35  |
| Se NPs          | 2.7 ± 0.3         | 3.6 ± 1.4     | 6.4 ± 2.01  | 7.3 ± 1.15  |
| MA plus Se NPs  | 1.5 ± 0.43        | 2.8 ± 1.15    | 3.3 ± 1.0   | 5.7 ± 1.15  |

* a: sensitive strain of *L. tropica/b: glucantime-resistant strain of *L. tropica*

**Leishmanicidal effects on amastigotes**

Biogenic Se NPs prepared by *Bacillus* sp. MSh-1 indicated a potent antileishmanial effect especially in combination with MA to the intramacrophage amastigotes of both strains after 72 h exposure. It could be observed that the anti-amastigote effects of Se NPs was based on a dose-dependent response, so that Se NPs induced the inhibition of the growth rate of amastigote forms within macrophage cells at concentrations of higher than 5 μg/mL when the mean number of amastigotes in each macrophage was assessed. However, when Se NPs combined with MA, the proliferation rate of amastigotes was significantly reduced (*P*<0.05) at concentration of higher than 2.5 μg/mL for both indices of amastigote-macrophage model as compared with positive control. The measured IC$_{50}$ values for Se NPs alone, MA alone and along with Se NPs against this parasitic form of sensitive and glucantime-resistant strains of *L. tropica* were also shown in Table 1.

Available at: [http://ijpa.tums.ac.ir](http://ijpa.tums.ac.ir)
**Inhibition of infection in macrophages**

Assessment of infectivity rate of the sensitive and glucantime-resistant strains of *L. tropica* promastigotes to the murine macrophage before and after treatment with the Se NPs indicated that promastigotes of both strains of *L. tropica* treated with no Se NPs were able to infect 78% and 81% of the macrophages, respectively. When promastigotes of both strains were pre-incubated with 1 μg/mL Se NPs for 2 h, they were able to infect only 16.3 and 21.6% of the murine macrophage cells respectively, in turn presenting reductions in their infectivity in the order of 79.3 and 73.3% for sensitive and glucantime-resistant strains of *L. tropica*, respectively (Table 2). Based on these results, it can be deduced that pre-treatment with the Se NPs was able to inhibit significantly the infection of *Leishmania* promastigotes into the murine macrophages.

**Table 2**: Inhibition of the infection in murine macrophages after treatment of sensitive and glucantime-resistant strains of *L. tropica* promastigotes with the meglumine antimoniate (MA) and biogenic selenium nanoparticles (Se NPs). Data are expressed as the mean ± SD (n = 3)

| Chemicals | Percentage of infected macrophages by non-treated promastigotes | Percentage of infected macrophages by treated promastigotes | Infectiveness Reduction (%) |
|-----------|---------------------------------------------------------------|---------------------------------------------------------------|----------------------------|
|           | SS\(^a\) RS\(^b\)                                            | SS\(^a\) RS\(^b\)                                            | SS RS                      |
| MA        | 78.6 ± 3.05 81 ± 3.6                                          | 34.6 ± 2.52 27.3 ± 2.15                                       | 56 66.3                    |
| Se NPs    | 78.6 ± 3.05 81 ± 3.6                                          | 16.3 ± 2.15 21.6 ± 2.52                                       | 79.3 73.3                  |

\(^a\): sensitive strain of *L. tropica*/\(^b\): Glucantime-resistant strain of *L. tropica*

**Hemolytic activity of Se NPs**

In evaluation of the hemolytic activity of Se NPs in O+ human RBCs, it could be seen no significant hemolytic activity at concentrations lower than 25 μg/mL. As compared with the positive control. However, Se NPs at concentrations of 25 and higher indicated significant hemolytic activity in O+ human RBCs.

**Discussion**

Leishmaniasis is a major public health problem in many countries around the world. The first line drugs, antimonials have been used for more than 65 years. In addition, other new drugs approved for the oral treatment of ACL and/or ZCL including miltefosine, ketoconazole, itraconazole, allopurinole, dapsone, and different physical therapies such as cryotherapy, surgical excision and heat are used (24-26). At present, the use of these drugs are limited due to high cost, toxicity, long-term treatment, partial effectiveness and the emergence of drug resistance (6-8). Recently, combination therapies with intra-lesional or systemic MA have been used for CL with different drugs, such as verapamil, allopurinole and imiquimod that proved their synergistic effects along with MA or sodium stibogluconate in treatment of CL (9, 11). Furthermore, in recent years, the use of nano drugs such as silver and gold nanoparticles to treat CL has been proven (27, 28).

Selenium compounds have extensive applications in medicine as anticancer, antioxidant and antimicrobial agents and their effects are related to immune system (6-8). Nanoparticles have been used for various medical applications due to their small nanoscale sizes and their high surface-to-volume ratios that allow more active sites for interacting with biological molecules such as microorganisms and other bioactive entities. On the other hand, nanoparticles provide a valuable feature to penetrate easily tissues with tumors and can eliminate cancerous cells without affecting the
normal tissues (6-8), Se NPs are able to reduce the development of HIV progression to AIDS and can inhibit the progression of hepatitis B and C to liver cancer (13, 29-31). In addition, it has been shown that Se NPs inhibit the growth of *Staphylococcus aureus* and pathogenic *Escherichia coli* (16, 17).

In this study, we evaluated the antileishmanial activity of biogenic Sc NPs alone and in combination with MA against sensitive and glucantime-resistant *L. tropica* on *in vitro*. The main reason for selection of this species was that the control of *L. tropica* is only by chemotherapy, which makes it vulnerable to resistance (7, 8). In the promastigote stage, the mean optical density (OD) and consequently IC₅₀ values for Se NPs along with MA against promastigote forms of both strains of *L. tropica* were lower than the Se NPs or MA alone.

This showed that the Se NPs were toxic to promastigotes and it might cause some morphological and biochemical changes such as DNA fragmentation during apoptotic cell death in the parasite as previously demonstrated elsewhere (19). Similarly, the Se NPs significantly reduced the viability of intramacrophage amastigotes of both strains and the mean infection rate of macrophages compared with each drug alone. Furthermore, we demonstrated that the infection rate of macrophages significantly decreased when promastigotes of both strains of *L. tropica* were pre-treated with Se NPs.

It has previously been shown that some protozoan including *Trypanosoma* and *Leishmania* and other higher microorganisms, need trace amounts of Se ions (32). However, we showed higher *in vitro* concentrations of Se NPs were toxic for both stages of sensitive and glucantime-resistant strains of *L. tropica*. Also in the present study it is found that promastigote forms were more susceptible to Se NPs (alone or in combination with MA) than amastigote forms. This difference in susceptibility of promastigote and amastigote stages against various concentrations of Se NPs might be related to structural, biochemical and morphological features (9, 33) and also other factors, including the phagolysosomal membrane of the macrophage, which reduce the entry of Se NPs into the macrophage cells and decrease the concentrations of Se NPs around the intramacrophage amastigotes (12, 19). In this study we reported that Se NPs at lower concentration had no hemolytic effect, whereas, the higher concentration of Se NPs showed more hemolytic effect on O+ human red blood cells.

Similar results were found by Beheshti et al. and Shakibaie et al. that demonstrated Se NPs at the low doses had no cytotoxic effects and could be considered safe (12, 19). Recently Shakibaie et al. have found that no biochemical changes were observed from the orally administration of 2.5, 5 and 10 mg/kg of Se NPs to male mice for two weeks, but a dose of 20 mg/kg of Se NPs indicated signs of toxicity including lower body weight and changes in clinical chemistry and hematological parameters (34). Moreover, they showed that the biogenic Se NPs were less toxic than synthetic Se NPs and much less (26-fold) toxic than the SeO₂.

**Conclusion**

High potency and synergistic effect of Se NPs alone and combined with MA in inhibiting growth of promastigote and amastigote stages of sensitive and glucantime-resistant strains of *L. tropica*. The results of this study suggest a first step in the search of Se NPs as a new antileishmanial agent. Further clinical studies are required to investigate the activity of the Se NPs as a new therapeutic agent against leishmaniasis.

**Acknowledgments**

This study was supported by the Kerman Leishmaniasis Research Center and Vice Chancellor for Research, Kerman University of Medical Sciences (project no.90/217). We
would like to thank Mr. Shokohi for data analysis and Mr. Ghasemi for cultivation of parasite. The authors declare that there is no conflict of interest in this study.

References

1. World Health Organization. Control of the Leishmaniasis. Geneva: WHO (Technical Report Series 949) 2010; 5-12.

2. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microb Infect Dis. 2004; 27: 305-18.

3. Sharifi F, Sharifi I, Zarean M Parizi MH, Aflatoonian M, Harandi MF, et al. Spatial distribution and molecular identification of Leishmania species from endemic foci of Southern-eastern Iran. Iran J Parasitol. 2012; 7(1): 45-52.

4. Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasser K, Mobasher F, et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine. 2009; 27(35): 4747-53.

5. Shirzadi MR, Gouya MM. National guideline for cutaneous leishmaniasis surveillance in Iran. Ministry of Health and Medical Education. Zoonoses control department, Tehran, I.R. Iran; 2010: pp 1-78.

6. Kazemi-Rad E, Mohebali M, Khadem-Erfan MB, Saffari M, Raoofian R, Hajarian H, et al. Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach. Exp Parasitol. 2013; 135(2): 344-9.

7. Pour R, Sharifi I, Kazemi B, Zarean M. Identification of nonresponsive isolates to Glucantime in patients with cutaneous leishmaniasis in Bam. J Kerman Univ Med Sci. 2011; 18(2): 123-33.

8. Santos DQ, Coutinho CE, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, et al. Leishmaniasis treatment – a challenge that remains: a review. Parasitol Res. 2004; 103: 1-10.

9. Mahmoudvand H, Sharififar F, Sharifi I, Ezatpour B, Fasih Harandi M, Makki MS, et al. In vitro inhibitory effect of Berberis vulgaris (Berberidaceae) and its main component, Berberine against different Leishmania species. Iran J Parasitol. 2014; 9 (1): 28-36.

10. Shamsi Meymandi S, Javadi A, Dahi S, Shamsi Meymandi M, Nadji M, et al. Comparative histological and immuno-histochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy. Arch Iran Med. 2011; 14 (4): 238-43.

11. Firooz A, Khamesipour A, Ghoorechi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis. Arch Dermatol. 2006; 142(12): 1575-9.

12. Shakiabe M, Khorramizadeh MR, Faramarzi MR, Sabzevari O, Shahverdi AR. Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression. Biotechnol Appl Biochem. 2010; 56: 7-15.

13. Rayman M. The importance of selenium to human health. Lancet. 2000; 356: 233-41.

14. Rayman M. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005; 64(4): 527-42.

15. Whanger PD. Selenium and its relationship to cancer: an update. Br J Nutr. 2004; 91: 11-28.

16. Tran AP, Webster T. Selenium nanoparticles inhibit Staphylococcus aureus growth. Int J Nano. 2011; 6: 1553-8.

17. Yang J, Huang K, Qin S, Wu X, Zhao Z, Chen F. Antibacterial action of selenium-enriched probiotics against pathogenic Escherichia coli. Dig Dis Sci. 2009; 54(2): 246-54.

18. Mahmoudvand H, Fasih Harandi M, Shakiabe M, Aflatoonian MR, Makki M, Jahanbakhsh S. Scolicidal effects of biogenic selenium nanoparticles against protoscolices of hydatid cysts. Int J Surg. 2014 Mar 28. doi: 10.1016/j.ijsu.2014.03.017. [Epub ahead of print].

19. Beheshti N, Soflaei S, Shakiabe M, Yazdi M, Ghaffarifar F, Dalimi AH, et al. Efficacy of biogenic selenium nanoparticles against Leishmania major: In vitro and in vivo studies. J Trace Elem Med Biol. 2012; 27(3): 203-7.

20. Mahmoudvand H, Sepahvand P, Jahanbakhsh S, Azadpour M. Evaluation of antileishmanial and cytotoxicity effects of various extracts of garlic (Allium sativum) on Leishmania tropica. J Parasit Dis. 2014 DOI: 10.1007/s12639-014-0520-9.
21. Mahmoudvand H, Sharifi I, Fasihi Harandi M, Shokohi M, Shakibaie M, Rezaei Riabi T, et al. Anti-leishmania effects of methotrexate (MTX) alone and in combination with meglumine antimoniate (MA) against Iranian isolate of sensitive and MA-resistant Leishmania tropica. An in-vitro assay. Asian Pacific J Trop Med. 2014; 4: 412-20.

22. Mahmoudvand H, Tavakoli R, Sharififar F, Minaie K, Ezatpour B, Jahanbakhsh B, et al. Leishmanicidal and cytotoxic activities of Nigella sativa and its active principle, thymoquinone. Pharm Biol. 2014 DOI: 10.3109/13880209.2014.957784.

23. Valadares DG, Duarte MC, Oliveira JS, Chávez-Fumagalli MA, Martins VT, Costa LE. Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species. Parasitol Int. 2011; 60: 357-63.

24. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006; 19(1): 11-26.

25. Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, Ouellette M, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmanial drugs. Parasitol Res. 2007; 101(5): 1319-22.

26. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoudi B, Rahnema A, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop. 2007; 103: 33-40.

27. Mohebali M, Rezayat MM, Gilani K, Sarkar S, Akhoudi B, Esmaeili J, et al. Nanosilver in the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO/IR-75/ER): an in vitro and in vivo study. Daru. 2009; 17 (4): 285-9.

28. Torabi N, Mohebali M, Shahverdi AR, Rezayat SM, Edrissian GH, Esmaeili J, et al. Nanogold for the treatment of zoonotic cutaneous leishmaniasis caused by Leishmania major (MRHO/IR/75/ER): An animal trial with methanol extract of Eucaalyptus camaldulensis. J Pharm Health Sci. 2011; 1(1): 15-18.

29. Baum MK, Shor-Posner G, Lai S, Zhang G, Lai H, Fletcher MA. High risk of HIV-related mortality is associated with selenium deficiency. J Acquir Immune Defic Syndr. 1997; 15: 370-4.

30. Yu M, Hong I, Chiang Y, Liaw Y, Chen C. Plasma selenium levels and the risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. Am J Epidemiol. 1999; 150: 367-74.

31. Yu S, Zhu Y, Li W. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res. 1997; 56: 117-24.

32. Lobanov AV, Gromer S, Salinas G, Gladyshev VN. Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastid-specific selenoprotein. Nucleic Acids Res. 2006; 34: 4012-24.

33. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Saks D. Evidence that the high incidence of treatment failure in Indian Kala azar is due the emergence of antimony resistant strains of Leishmania donovani. J Infect Dis. 1999; 180(2): 564-7.

34. Shakibaie M, Shahverdi AR, Faramarzi MR, Hassanzadeh GR, Rahimi HR, Sabzevari O. Acute and subacute toxicity of novel biogenic selenium nanoparticles in mice. Pharma Biol. 2013; 51(1): 58-63.